Azenta Guides FY27 Revenue to $648-$660M as Organic Growth Stalls at 2%
AZTA has more than doubled off its 52-week low of $15.93.
Summary
Azenta closed fiscal 2026 with Q4 revenue of $167 million, up 5% reported but only 2% organic, and full-year revenue of $622 million on the same 5%/2% split. The headline problem is profitability: FY26 adjusted EBITDA fell to $58.3 million (9.4% margin) from $66.3 million (11.2%), and GAAP results carried a $149 million non-cash goodwill impairment taken in Q2, driving a full-year diluted loss from continuing operations of $3.50 per share. Q4 EPS came in at 16c, while Q4 adjusted diluted EPS of $0.28 did beat last year's $0.21, and gross margin improved 60 bps to 46.0%, so the second half did show better momentum under interim CEO Dr. Martin Madaus. FY27 guidance calls for revenue of $648-$660 million, 3-5% organic growth, and 200-250 bps of adjusted EBITDA margin expansion — but that margin number includes roughly 100 bps of dilution from the Elegen license and SynPlexity acquisition closed in late October, so underlying improvement is thinner than the headline range suggests. Free cash flow is guided to improve about 25% off FY26's $27 million, a low base. The setup follows a turbulent stretch: CEO John Marotta resigned in August, the Multiomics restructuring closed three North American labs in October, and material weaknesses in internal controls remain outstanding from the Q3 10-Q. The earnings call is November 11 at 8:30 a.m. ET.
At the time of this announcement, AZTA was trading at $39.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $15.93 to $46.41. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.